Science University Research Symposium (SURS)
Targeting Lysosomal Dysfunction with Rapamycin in Tay-Sachs Disease
Publication Date
Fall 2026
College
College of Sciences & Mathematics
Department
Biology, Department of
SURS Faculty Advisor
Dr. Felicity Sterling
Presentation Type
Poster Presentation
Abstract
Tay-Sachs disease is a genetic disorder caused by mutations in the HEXA gene, which lead to a deficiency in the enzyme β-hexosaminidase A (HexA). Without enough of this enzyme, GM2 gangliosides cannot be properly broken down and begin to accumulate in lysosomes. This buildup affects normal cell function and contributes to neuronal damage. Lysosomal dysfunction may also affect mitochondria by interfering with mitophagy, the process cells use to get rid of damaged mitochondria. If these mitochondria are not removed, they can build up and contribute to cell death. Rapamycin, an inhibitor of mTORC1, is being studied because this pathway is known to regulate autophagy. Blocking mTORC1 may help increase autophagic activity and improve the removal of damaged mitochondria.
The purpose of this study is to examine mitochondrial damage and autophagy in a cellular model of Tay-Sachs disease and determine whether rapamycin can improve mitochondrial quality control. Wild-type (WT) and disease-model COS-7 cells were examined using mitochondrial fragmentation staining and LC3 immunofluorescence. Living and dead mitochondrial structures were counted to compare mitochondrial damage between the two cell types. LC3 staining was also used to examine autophagosome accumulation. Rapamycin treatment is being investigated to see whether it can affect autophagy and mitochondrial clearance.
Initial results showed a difference between WT and disease-model cells. WT cells had an average of 4.3 living and 2.7 dead mitochondrial structures per image. Disease-model cells had an average of 0.9 living and 10.1 dead structures per image. The higher number of dead mitochondrial structures in the disease-model cells suggests that they experience more mitochondrial damage than WT cells. Further analysis of LC3 staining and rapamycin-treated cells is needed to determine whether autophagy is affected and whether treatment can improve mitochondrial clearance.
It is expected that rapamycin will increase autophagic activity and help remove damaged mitochondria. This study aims to better understand how lysosomal dysfunction affects mitochondria in Tay-Sachs disease and whether targeting mTORC1 could help reduce some of the resulting cellular damage.
Recommended Citation
Siddiq, Sheza; Hays, Gabby; and Sterling, Felicity, "Targeting Lysosomal Dysfunction with Rapamycin in Tay-Sachs Disease" (2026). Science University Research Symposium (SURS). 351.
https://repository.belmont.edu/surs/351
